Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
Category: #health  By Pankaj Singh  Date: 2019-09-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing on developing new drugs by means of novel clinical trials.

POXEL S.A., a biopharmaceutical company focused on developing novel treatments and drugs for metabolic disorders like non-alcoholic steatohepatitis (NASH) and type 2 diabetes, recently presented a detailed Phase 3 results from the TIMES (Trials of Imeglimin for Efficacy and Safety) 1 program.

According to reports, the data would be displayed in a symposium session at the 55th Annual Meeting of EASD (European Association for the Study of Diabetes), conducted in Barcelona, Spain.

Speaking on the move, Ralph DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio, said that to effectively administer type 2 diabetes, treatments need to fix both the defects in insulin sensitivity and insulin secretion.

He added that Poxel’s new treatment is an innovative therapeutic approach with an exclusive mechanism of action that operates on the level of the mitochondria. Moreover, by advancing mitochondrial function, the drug has shown a rise in insulin secretion and muscle insulin sensitivity while decreasing hepatic glucose production.

Previously, the company had partnered with Sumitomo Dainippon Pharma Co., Ltd, to announce encouraging top-line Phase 3 results for Imeglimin TIMES 3 16-week, placebo-controlled, randomized, double-blind clinical trial aimed to treat type 2 diabetes in Japan.

Reportedly, the Phase 3 study in Japan involved three crucial trials to assess Imeglimin’s safety and efficacy across 1,100 patients.

According to Prof. Hirotaka Watada, MD, PhD, Professor at Department of Metabolism & Endocrinology, Juntendo University, Tokyo, Imeglimin’s unique mechanism of action that focuses on very significant deficiencies occurring in diabetes combined with its safety profile, could massively improve the health of Japanese patients who earlier relied on insulin.

Source Credit: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/128/poxel-announces-detailed-imeglimin-phase-3-times-1-results



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...